BMS misses a beat in cancer comeback

Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their bladder drug vinflunine. The therapy had been a key part of BMS's strategy for a comeback in cancer therapies. Feedback from the FDA prompted the reversal. BMS is expected to seek approval soon for the melanoma drug ipilimumab, which is being developed in partnership with Medarex.

- here's the report
- and here's an article from Scientific American on BMS' cancer efforts

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.